Definitive Therapy for Oligometastatic Solid Malignancies
| Status: | Recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/2/2016 |
| Start Date: | December 2005 |
| End Date: | December 2018 |
| Contact: | Rachel Lei, BS |
| Email: | rachel.lei@usoncology.com |
| Phone: | 303-418-7607 |
A Prospective Investigation of Definitive Targeted Therapy for Solid Malignancies With Oligometastases
Patients with metastatic cancer are usually treated with systemic therapy (treating the
entire body) with the assumption that any localized treatment of clinically apparent
metastases would not impact survival. In the setting of increasingly effective systemic
therapy and limited metastatic disease, aggressive treatment to clinically active sites of
disease (alone or in addition to systemic therapy) may improve survival.
entire body) with the assumption that any localized treatment of clinically apparent
metastases would not impact survival. In the setting of increasingly effective systemic
therapy and limited metastatic disease, aggressive treatment to clinically active sites of
disease (alone or in addition to systemic therapy) may improve survival.
Up to recently it has been assumed that in the setting of metastatic solid tumors,
locoregional control of clinically apparent metastases does not substantially impact
survival due to undetectable micrometastic (clinically not visualized) disease that
ultimately lead to treatment failure/progression. However, as more advanced systemic therapy
continue to improve control of micrometastatic disease, failures at the original sites of
disease remain common. Furthermore, some studies have shown locoregional treatment of
limited clinical metastases to actually improve survival. Therefore, the investigators
hypothesize that aggressive treatment to clinically active sites of disease (alone or in
addition to systemic therapy) may improve survival or alter the course of the disease in
some patients with limited metastatic disease.
locoregional control of clinically apparent metastases does not substantially impact
survival due to undetectable micrometastic (clinically not visualized) disease that
ultimately lead to treatment failure/progression. However, as more advanced systemic therapy
continue to improve control of micrometastatic disease, failures at the original sites of
disease remain common. Furthermore, some studies have shown locoregional treatment of
limited clinical metastases to actually improve survival. Therefore, the investigators
hypothesize that aggressive treatment to clinically active sites of disease (alone or in
addition to systemic therapy) may improve survival or alter the course of the disease in
some patients with limited metastatic disease.
Inclusion Criteria:
- 4 or less distinct sites of active disease. Locoregional disease counts as one site
- All sites of disease can safely be encompassed by radiation fields to doses ≥ 45 Gy
(biologic equivalent dose) and/or removed completely with surgery and/or completely
ablated with other appropriate site-specific techniques.
- sufficient blood cell counts and adequate liver function
Exclusion Criteria:
- Hematologic malignancies
- Distinct sites of disease > 4
- Karnofsky Performance Status < 70
- Unexplained weight loss > 10 %
- HIV, chronic viral hepatitis, or any chronically active infection
- Life expectancy < 6 months for any reason
We found this trial at
4
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials